FIGURE 7.

Vorinostat does not delay weight loss or penetrate the blood-brain barrier of Npc1^nmf164 mice. a, animals were treated with PEG/DMSO or 150 mg/kg vorinostat between P21 and P90 (3–13 weeks) and weighed weekly. Data are shown as mean ± S.D. (error bars) for WT + PEG/DMSO (n = 5), WT + PEG/DMSO (n = 5), Npc1^nmf164 + PEG/DMSO (n = 5), and Npc1^nmf164 + vorinostat (n = 6). *, p < 0.05, two-way analysis of variance with Bonferroni post hoc test. b and c, vorinostat levels in the brain are <5% of plasma levels. 150 mg/kg vorinostat was administered in Npc1^nmf164 mice at P21, and mean vorinostat levels were quantified in the plasma and brain at four time points after injection (0.5, 1, 2, and 4 h).